Zivo Bioscience Inc
zivobioscience.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 14, 2025. Its latest SEC filing is a 4 from Apr 24, 2026.
10-Q for Q3 FY2025, filed Nov 14, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops algae-derived therapeutic candidates for animal and human health and sells dried algae powder as a food product to consumers.
10-K for FY2024, filed Mar 18, 2025We are a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio…View ↗
Our strategy is to develop bioactive extracts, fractions, and molecules derived from our proprietary algal culture, targeting human and…View ↗
For the nutrition side of our business, we have developed our proprietary algal culture to be commercially viable as a nutritional product.…View ↗
In June 2023, ZIVOLife commenced commercial shipments of our dried green algae powder intended for human consumption as a food or food…View ↗
How Did They Make Money?
The company sells dried green algae powder as a human food or food ingredient to a distributor, which sells it to consumers; it is paid when the product is delivered to the customer.
10-K for FY2024, filed Mar 18, 2025The Company earns revenue through the sales of its proprietary microalgae products which are presently sold as a dried green powder…View ↗
Cost of goods sold for the Company included purchasing our proprietary dried green microalgae in a final packaged form from a contract…View ↗
Revenue is recognized in accordance with ASC 606, which utilizes five steps to determine whether revenue can be recognized and to what…View ↗
$157.2K
-
10-K for FY2024, filed Mar 18, 2025
$157.2K ↗
Who Were Their Customers?
A distributor buys the dried algae product from ZIVO and sells it directly to consumers through its branded online store.
10-K for FY2024, filed Mar 18, 2025The Company earns revenue through the sales of its proprietary microalgae products which are presently sold as a dried green powder…View ↗
Cost of goods sold for the Company included purchasing our proprietary dried green microalgae in a final packaged form from a contract…View ↗
In September 2022, the Company through its ZIVOLife LLC subsidiary entered into a Marketing, Sales, and Distribution Agreement…View ↗
10-K for FY2024, filed Mar 18, 2025
For the year ended December 31, 2024, the Company had only one product for sale, and one customer accounted for 100% of the revenue for its…View ↗
Did Revenues Turn Into Profits?
No. It lost $13.4M in FY2024.
10-K for FY2024, filed Mar 18, 2025
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Nov 14, 2025
−$1MView ↗
- ▼ −54% (Loss)
- vs −$2.3M in Q3 FY2024
-
Mar 30, 2026
Interim CFO resigns as ZIVO announces plans to delist
The company said it intends to file Form 15 to suspend reporting obligations and voluntarily delist its common stock and warrants from OTC markets.
Sources
8-K, filed Mar 30, 2026
ZIVO intends to file a Form 15 to deregister its securities and suspend its reporting obligations on or around March 30, 2026. The filing…View ↗
-
Dec 23, 2025
The chief financial officer resigned and an interim CFO was appointed
Keith R. Marchiando resigned as CFO, and William A. Sullivan was appointed interim CFO.
Sources
8-K, filed Dec 23, 2025
On December 19, 2025, Keith R. Marchiando announced his intention to resign as Chief Financial Officer of Zivo Bioscience, Inc. (the…View ↗
Grew. Revenue grew 7.9x in 4 years, from $20K in FY2020 to $157.2K in FY2024, about 67% a year.
A commercial algae food product
The older report described algae biomass as a potential food ingredient with contracts but no sales expected before production expansion. The latest report describes commercial shipments of dried algae powder for human consumption through a distributor.
10-K for FY2021, filed Apr 22, 2022 10-K for FY2024, filed Mar 18, 2025ZIVO’s algal biomass is currently produced in Peru. ZIVO’s algal biomass contains Vitamin A, protein, iron, important fatty acids…View ↗
Who Did They Compete With?
Competes with HuvePharma, Elanco, Zoetis, Phibro, Boehringer Ingelheim, Merck Animal Health, Bayer, Vetoquinol, Ceva Sante Animale, Virbac Group, Norbrook Laboratories, Dechra Pharmaceuticals, Eisai Research Institute of Boston, Takeda Pharmaceutical, Earthrise, Cyanotech, AG1, DSM, Cognis, and ConAgra
10-K for FY2024, filed Mar 18, 2025Poultry Gut Health and Avian Influenza: Conventional poultry production typically involves the use of ionophores, other anticoccidial…View ↗
Loading...
